Schwab executive: Bitcoin did not crash because of Saylor, but rather due to losing its leading position in momentum trading
According to ChainCatcher, CoinDesk reported that Jim Ferraioli, Director of Digital Asset Research at Charles Schwab, stated that Bitcoin’s recent weakness is not due to fading institutional demand or Michael Saylor selling Bitcoin, but rather because it is losing its place as the dominant vehicle for momentum trading in the market.
He pointed out that crypto investors have historically followed momentum, and currently, momentum has shifted away from the crypto space. Capital is flowing into popular narratives such as artificial intelligence-related stocks and IPOs. SpaceX’s IPO could be valued at up to 1.8 trillion dollars, and a batch of other IPOs together could raise more than 200 billion dollars, draining liquidity from the crypto market. Crypto traders are also speculating on pre-IPO stocks through synthetic derivative contracts on DEXs like Hyperliquid.
Ferraioli downplayed the impact of Strategy selling 32 Bitcoin, suggesting it merely provides a convenient narrative for an already existing broader trend. He noted that while Bitcoin ETFs have expanded access, the asset class remains predominantly led by retail and momentum traders. Summer has historically been a seasonally weak period for Bitcoin, and there is currently a lack of reasons to buy, since investors now have alternative options.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
